<DOC>
	<DOCNO>NCT03001882</DOCNO>
	<brief_summary>The purpose study explore possible link patient characteristic cancer , effective combination nivolumab ipilimumab , patient Stage IV recurrent Non-Small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>An Exploratory Study Effects Nivolumab Combined With Ipilimumab Patients With Treatment-Naive Stage IV Recurrent Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Histologically confirm , stage IV recurrent nonsmall cell lung cancer prior systemic anticancer therapy give primary therapy advance metastatic disease Measurable disease CT MRI Must full activity , limited , must able walk carry light activity light house work office work Patients untreated central nervous system metastases Participants active , know suspected autoimmune disease Prior treatment drug target T cell costimulations pathway ( checkpoint inhibitor ) Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>